L. Guerenne

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways

G. Mufti, V. Vanneaux, L. Sarda-Mantel, 2016, Journal of Hematology & Oncology.

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice

V. Mathews, P. Fenaux, L. Adès, 2015, Blood Cancer Journal.

DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies

V. Mathews, P. Fenaux, N. Tekin, 2015, Oncotarget.

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome

P. Merlet, M. Konopleva, M. Andreeff, 2021, International journal of molecular sciences.